207 related articles for article (PubMed ID: 38833073)
1. Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression.
Ando K; Küçükali F; Doeraene E; Nagaraj S; Antonelli EM; Thazin Htut M; Yilmaz Z; Kosa AC; Lopez-Guitierrez L; Quintanilla-Sánchez C; Aydin E; Ramos AR; Mansour S; Turbant S; Schurmans S; Sleegers K; Erneux C; Brion JP; Leroy K;
Acta Neuropathol; 2024 Jun; 147(1):94. PubMed ID: 38833073
[TBL] [Abstract][Full Text] [Related]
2. FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model.
Kam TI; Park H; Gwon Y; Song S; Kim SH; Moon SW; Jo DG; Jung YK
Elife; 2016 Nov; 5():. PubMed ID: 27834631
[TBL] [Abstract][Full Text] [Related]
3. INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia.
Tsai AP; Lin PB; Dong C; Moutinho M; Casali BT; Liu Y; Lamb BT; Landreth GE; Oblak AL; Nho K
Neurobiol Dis; 2021 Jun; 153():105303. PubMed ID: 33631273
[TBL] [Abstract][Full Text] [Related]
4. The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer's disease.
Ando K; Ndjim M; Turbant S; Fontaine G; Pregoni G; Dauphinot L; Yilmaz Z; Suain V; Mansour S; Authelet M; De Dekker R; Leroy K; Delatour B; ; Duyckaerts C; Potier MC; Brion JP
Acta Neuropathol Commun; 2020 Jun; 8(1):79. PubMed ID: 32493451
[TBL] [Abstract][Full Text] [Related]
5. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.
Cruchaga C; Kauwe JS; Mayo K; Spiegel N; Bertelsen S; Nowotny P; Shah AR; Abraham R; Hollingworth P; Harold D; Owen MM; Williams J; Lovestone S; Peskind ER; Li G; Leverenz JB; Galasko D; ; Morris JC; Fagan AM; Holtzman DM; Goate AM
PLoS Genet; 2010 Sep; 6(9):e1001101. PubMed ID: 20862329
[TBL] [Abstract][Full Text] [Related]
6. Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice.
Farfara D; Sooliman M; Avrahami L; Royal TG; Amram S; Rozenstein-Tsalkovich L; Trudler D; Blanga-Kanfi S; Eldar-Finkelman H; Pahnke J; Rosenmann H; Frenkel D
J Neuroinflammation; 2023 Jul; 20(1):174. PubMed ID: 37496076
[TBL] [Abstract][Full Text] [Related]
7. Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.
Lim JW; Kim SK; Choi SY; Kim DH; Gadhe CG; Lee HN; Kim HJ; Kim J; Cho SJ; Hwang H; Seong J; Jeong KS; Lee JY; Lim SM; Lee JW; Pae AN
Eur J Med Chem; 2018 Sep; 157():405-422. PubMed ID: 30103190
[TBL] [Abstract][Full Text] [Related]
8. Aberrant accrual of BIN1 near Alzheimer's disease amyloid deposits in transgenic models.
De Rossi P; Andrew RJ; Musial TF; Buggia-Prevot V; Xu G; Ponnusamy M; Ly H; Krause SV; Rice RC; de l'Estoile V; Valin T; Salem S; Despa F; Borchelt DR; Bindokas VP; Nicholson DA; Thinakaran G
Brain Pathol; 2019 Jul; 29(4):485-501. PubMed ID: 30506549
[TBL] [Abstract][Full Text] [Related]
9. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
10. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
[TBL] [Abstract][Full Text] [Related]
11. Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation.
Hoekstra E; Das AM; Willemsen M; Swets M; Kuppen PJ; van der Woude CJ; Bruno MJ; Shah JP; Ten Hagen TL; Chisholm JD; Kerr WG; Peppelenbosch MP; Fuhler GM
Oncotarget; 2016 Nov; 7(45):73525-73540. PubMed ID: 27716613
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
13. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
14. Altered chondrocyte differentiation, matrix mineralization and MEK-Erk1/2 signaling in an INPPL1 catalytic knock-out mouse model of opsismodysplasia.
Vande Catsyne CA; Sayyed SA; Molina-Ortiz P; Moes B; Communi D; Muller J; Heusschen R; Caers J; Azzi A; Erneux C; Schurmans S
Adv Biol Regul; 2020 May; 76():100651. PubMed ID: 31519471
[TBL] [Abstract][Full Text] [Related]
15. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
16. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
17. Alcohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease.
Hoffman JL; Faccidomo S; Kim M; Taylor SM; Agoglia AE; May AM; Smith EN; Wong LC; Hodge CW
Int Rev Neurobiol; 2019; 148():169-230. PubMed ID: 31733664
[TBL] [Abstract][Full Text] [Related]
18. Aβ modulates actin cytoskeleton via SHIP2-mediated phosphoinositide metabolism.
Lee HN; Sim KM; Kim H; Ju J; Pae AN; Park JB; Ryu H; Seong J
Sci Rep; 2019 Oct; 9(1):15557. PubMed ID: 31664099
[TBL] [Abstract][Full Text] [Related]
19. Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease.
Zhou Y; Hayashi I; Wong J; Tugusheva K; Renger JJ; Zerbinatti C
PLoS One; 2014; 9(7):e103187. PubMed ID: 25051234
[TBL] [Abstract][Full Text] [Related]
20. Distinctive temporal profiles of detergent-soluble and -insoluble tau and Aβ species in human Alzheimer's disease.
Koss DJ; Dubini M; Buchanan H; Hull C; Platt B
Brain Res; 2018 Nov; 1699():121-134. PubMed ID: 30102892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
